US Bancorp DE Sells 2,803 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

US Bancorp DE trimmed its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 42.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,746 shares of the biotechnology company’s stock after selling 2,803 shares during the period. US Bancorp DE’s holdings in Sarepta Therapeutics were worth $455,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Janus Henderson Group PLC raised its holdings in Sarepta Therapeutics by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after buying an additional 543,143 shares during the period. Wellington Management Group LLP grew its stake in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after buying an additional 665,087 shares in the last quarter. Geode Capital Management LLC boosted its position in Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after purchasing an additional 44,306 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in Sarepta Therapeutics by 9.2% during the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock worth $94,148,000 after purchasing an additional 63,437 shares during the period. Finally, Erste Asset Management GmbH bought a new position in Sarepta Therapeutics during the third quarter worth $79,425,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on SRPT shares. Scotiabank assumed coverage on shares of Sarepta Therapeutics in a research report on Friday, March 7th. They issued a “sector perform” rating and a $105.00 target price for the company. Deutsche Bank Aktiengesellschaft assumed coverage on Sarepta Therapeutics in a research note on Tuesday, February 11th. They set a “hold” rating and a $136.00 target price for the company. Royal Bank of Canada reduced their price target on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Needham & Company LLC restated a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $170.41.

Sarepta Therapeutics Trading Down 0.9 %

Shares of Sarepta Therapeutics stock opened at $99.77 on Thursday. Sarepta Therapeutics, Inc. has a 1 year low of $97.91 and a 1 year high of $173.25. The firm has a market cap of $9.68 billion, a PE ratio of 79.82 and a beta of 0.79. The stock has a fifty day moving average price of $112.83 and a 200-day moving average price of $120.55. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.